VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)

The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm) was developed and approved for the treatment of portal hypertension and its complications such as bleeding from enlarged or swollen veins (variceal bleeding) and abnormal build-up of fluid in the abdomen that does not respond to therapy (ascites which recurs despite conventional treatment).

Subjects will receive the Registry Device as part of standard treatment for their condition. This means within this Registry, the information collected reflects the use of the Registry Device in typical, everyday medical practice by physicians, often referred to as "real world" data.

Patient total sample size will target a total approximately 152 patients treated with GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm).

Subjects who meet all criteria may be enrolled in the Registry.

The first visit after the procedure will be performed at the day of discharge or within 7 days after the procedure, whatever comes first. Subjects will have follow-up visits at 1 month, 3 months, 6 months, 12 months, and 24 months after their procedure so their health and the performance of the Registry Device can be monitored.

During follow-up visits, the doctor will perform a physical exam, review medications, and perform a condition status assessment. Imaging will not be collected as part of the Registry but may be ordered by the doctor for safety follow-up purposes as imaging is often collected as part of standard medical care.

Subjects will be asked to complete Quality of Life questionnaires at each follow-up visit to collect information on their well-being and daily life.

Inclusion criteria

• The subject is eligible for treatment with the GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion 6-10mm for de novo TIPS creation.
• The subject has cirrhotic portal hypertension.
• The subject is ≥18 years of age.
• The subject is capable of complying with protocol requirements, including follow up.
• The subject or legal representative signed the informed consent form (ICF).

Exclusion criteria

• The subject has any portal vein thrombosis, including both occlusive and non-occlusive thrombosis.
• The subject has received a liver transplantation. Patients on the transplant list are still eligible.
• The subject has a life expectancy of less than 6 months.
• The subject has extrahepatic or hepatic malignancy or a history of previous malignancy, unless treated curatively ≥5 years prior to enrollment. Subjects with non-melanoma skin cancer and/or carcinoma in situ of the cervix remain eligible.
• The subject has inadequate functional hepatic reserve with a Model for End-Stage Liver Disease (MELD) Score of > 25 or Child Pugh Score of > 14.
• The subject is enrolled in another investigational study, unless agreed in advance in writing by the Sponsor.
• The subject is pregnant at the time of informed consent signature.
• The subject has any other condition which in the judgement of the investigator would preclude adequate Study participation.